NCT04152915View on ClinicalTrials.gov

A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens

PHASE1CompletedINTERVENTIONAL

Enrollment

68

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

May 25, 2020

Study Completion Date

May 25, 2020

Conditions

Healthy VolunteersDiabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 7 weeks

Trial Locations (1)

55116

Novo Nordisk Investigational Site, Mainz

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY

NCT04152915 - A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens | Biotech Hunter | Biotech Hunter